Onsdag 4 December | 12:25:29 Europe / Stockholm

Kalender

Tid*
2025-10-28 11:00 Kvartalsrapport 2025-Q3
2025-07-18 11:00 Kvartalsrapport 2025-Q2
2025-04-23 11:00 Kvartalsrapport 2025-Q1
2025-04-03 N/A Årsstämma
2025-02-25 12:30 Bokslutskommuniké 2024
2024-10-29 - Kvartalsrapport 2024-Q3
2024-10-15 - X-dag halvårsutdelning ORNAV 0.81
2024-10-15 - X-dag halvårsutdelning ORNBV 0.81
2024-08-08 - Kvartalsrapport 2024-Q2
2024-04-25 - Kvartalsrapport 2024-Q1
2024-03-21 - X-dag halvårsutdelning ORNAV 0.81
2024-03-21 - X-dag halvårsutdelning ORNBV 0.81
2024-03-20 - Årsstämma
2024-02-13 - Bokslutskommuniké 2023
2023-10-26 - Kvartalsrapport 2023-Q3
2023-07-17 - Kvartalsrapport 2023-Q2
2023-04-27 - Kvartalsrapport 2023-Q1
2023-03-23 - X-dag ordinarie utdelning ORNAV 1.60 EUR
2023-03-23 - X-dag ordinarie utdelning ORNBV 1.60 EUR
2023-03-22 - Årsstämma
2023-02-09 - Bokslutskommuniké 2022
2022-10-20 - Kvartalsrapport 2022-Q3
2022-07-15 - Kvartalsrapport 2022-Q2
2022-04-28 - Kvartalsrapport 2022-Q1
2022-03-24 - X-dag ordinarie utdelning ORNAV 1.50 EUR
2022-03-24 - X-dag ordinarie utdelning ORNBV 1.50 EUR
2022-03-23 - Årsstämma
2022-02-10 - Bokslutskommuniké 2021
2021-10-20 - Kvartalsrapport 2021-Q3
2021-07-19 - Kvartalsrapport 2021-Q2
2021-04-27 - Kvartalsrapport 2021-Q1
2021-03-26 - X-dag ordinarie utdelning ORNAV 1.50 EUR
2021-03-26 - X-dag ordinarie utdelning ORNBV 1.50 EUR
2021-03-25 - Årsstämma
2021-02-09 - Bokslutskommuniké 2020
2020-10-21 - Kvartalsrapport 2020-Q3
2020-07-17 - Kvartalsrapport 2020-Q2
2020-05-07 - X-dag ordinarie utdelning ORNAV 1.50 EUR
2020-05-07 - X-dag ordinarie utdelning ORNBV 1.50 EUR
2020-05-06 - Årsstämma
2020-04-28 - Kvartalsrapport 2020-Q1
2020-03-26 - X-dag ordinarie utdelning ORNBV 1.50 EUR
2020-02-05 - Bokslutskommuniké 2019
2019-10-23 - Kvartalsrapport 2019-Q3
2019-07-17 - Kvartalsrapport 2019-Q2
2019-04-25 - Kvartalsrapport 2019-Q1
2019-03-27 - X-dag ordinarie utdelning ORNAV 1.50 EUR
2019-03-27 - X-dag ordinarie utdelning ORNBV 1.50 EUR
2019-03-26 - Årsstämma
2019-02-06 - Bokslutskommuniké 2018
2018-10-24 - Kvartalsrapport 2018-Q3
2018-07-18 - Kvartalsrapport 2018-Q2
2018-04-24 - Kvartalsrapport 2018-Q1
2018-03-21 - X-dag ordinarie utdelning ORNAV 1.45 EUR
2018-03-21 - X-dag ordinarie utdelning ORNBV 1.45 EUR
2018-03-20 - Årsstämma
2018-02-07 - Bokslutskommuniké 2017
2017-10-26 - Kvartalsrapport 2017-Q3
2017-07-19 - Kvartalsrapport 2017-Q2
2017-05-18 - Kapitalmarknadsdag 2017
2017-04-26 - Kvartalsrapport 2017-Q1
2017-03-23 - X-dag ordinarie utdelning ORNAV 1.35 EUR
2017-03-23 - X-dag bonusutdelning ORNAV 0.2
2017-03-23 - X-dag ordinarie utdelning ORNBV 1.35 EUR
2017-03-23 - X-dag bonusutdelning ORNBV 0.2
2017-03-22 - Årsstämma
2017-02-08 - Bokslutskommuniké 2016
2016-10-25 - Kvartalsrapport 2016-Q3
2016-07-19 - Kvartalsrapport 2016-Q2
2016-04-27 - Kvartalsrapport 2016-Q1
2016-03-23 - X-dag ordinarie utdelning ORNAV 1.30 EUR
2016-03-23 - X-dag ordinarie utdelning ORNBV 1.30 EUR
2016-03-22 - Årsstämma
2016-02-02 - Bokslutskommuniké 2015
2015-10-27 - Kvartalsrapport 2015-Q3
2015-07-28 - Kvartalsrapport 2015-Q2
2015-05-26 - Kapitalmarknadsdag 2015
2015-04-29 - Kvartalsrapport 2015-Q1
2015-03-25 - X-dag ordinarie utdelning ORNAV 1.30 EUR
2015-03-25 - X-dag ordinarie utdelning ORNBV 1.30 EUR
2015-03-24 - Årsstämma
2015-02-04 - Bokslutskommuniké 2014
2014-10-21 - Kvartalsrapport 2014-Q3
2014-07-29 - Kvartalsrapport 2014-Q2
2014-04-29 - Kvartalsrapport 2014-Q1
2014-03-26 - X-dag ordinarie utdelning ORNAV 1.25 EUR
2014-03-26 - X-dag ordinarie utdelning ORNBV 1.25 EUR
2014-03-25 - Årsstämma
2014-02-04 - Bokslutskommuniké 2013
2013-10-22 - Kvartalsrapport 2013-Q3
2013-07-30 - Kvartalsrapport 2013-Q2
2013-04-23 - Kvartalsrapport 2013-Q1
2013-03-20 - X-dag ordinarie utdelning ORNAV 1.30 EUR
2013-03-20 - X-dag ordinarie utdelning ORNBV 1.30 EUR
2013-03-19 - Årsstämma
2013-02-05 - Bokslutskommuniké 2012
2012-10-23 - Kvartalsrapport 2012-Q3
2012-07-31 - Kvartalsrapport 2012-Q2
2012-05-24 - Kapitalmarknadsdag 2012
2012-04-24 - Kvartalsrapport 2012-Q1
2012-03-21 - X-dag ordinarie utdelning ORNAV 1.30 EUR
2012-03-21 - X-dag bonusutdelning ORNAV 0.12
2012-03-21 - X-dag ordinarie utdelning ORNBV 1.30 EUR
2012-03-21 - X-dag bonusutdelning ORNBV 0.12
2012-03-20 - Årsstämma
2012-02-07 - Bokslutskommuniké 2011
2011-10-25 - Kvartalsrapport 2011-Q3
2011-08-02 - Kvartalsrapport 2011-Q2
2011-04-27 - Kvartalsrapport 2011-Q1
2011-04-01 - X-dag ordinarie utdelning ORNAV 1.20 EUR
2011-04-01 - X-dag bonusutdelning ORNAV 0.06
2011-04-01 - X-dag ordinarie utdelning ORNBV 1.20 EUR
2011-04-01 - X-dag bonusutdelning ORNBV 0.06
2011-03-31 - Årsstämma
2011-02-09 - Bokslutskommuniké 2010
2010-10-26 - Kvartalsrapport 2010-Q3
2010-08-10 - Kvartalsrapport 2010-Q2
2010-04-27 - Kvartalsrapport 2010-Q1
2010-03-25 - X-dag ordinarie utdelning ORNAV 1.00 EUR
2010-03-25 - X-dag bonusutdelning ORNAV 0.1
2010-03-25 - X-dag ordinarie utdelning ORNBV 1.00 EUR
2010-03-25 - X-dag bonusutdelning ORNBV 0.1
2009-03-24 - X-dag ordinarie utdelning ORNAV 0.95 EUR
2009-03-24 - X-dag ordinarie utdelning ORNBV 0.95 EUR
2008-03-26 - X-dag ordinarie utdelning ORNBV 1.00 EUR
2007-04-03 - X-dag ordinarie utdelning ORNAV 1.00 EUR
2007-04-03 - X-dag ordinarie utdelning ORNBV 1.00 EUR
2006-03-22 - X-dag ordinarie utdelning ORNBV 0.85 EUR
2005-03-22 - X-dag ordinarie utdelning ORNAV 0.55 EUR
2005-03-22 - X-dag ordinarie utdelning ORNBV 0.55 EUR
2004-09-15 - X-dag bonusutdelning ORNAV 2.14
2004-09-15 - X-dag bonusutdelning ORNBV 2.14
2004-03-23 - X-dag ordinarie utdelning ORNAV 1.60 EUR
2004-03-23 - X-dag ordinarie utdelning ORNBV 1.60 EUR
2003-12-12 - X-dag bonusutdelning ORNAV 1.5
2003-12-12 - X-dag bonusutdelning ORNBV 1.5
2003-03-23 - X-dag ordinarie utdelning ORNAV 0.93 EUR
2003-03-23 - X-dag ordinarie utdelning ORNBV 0.93 EUR
2002-04-16 - X-dag ordinarie utdelning ORNAV 1.10 EUR
2002-04-16 - X-dag ordinarie utdelning ORNBV 1.10 EUR
2001-03-30 - X-dag ordinarie utdelning ORNAV 1.20 EUR
2001-03-30 - X-dag ordinarie utdelning ORNBV 1.20 EUR
2000-03-31 - X-dag ordinarie utdelning ORNAV 1.18 EUR
2000-03-31 - X-dag ordinarie utdelning ORNBV 1.18 EUR
1999-07-28 - X-dag bonusutdelning ORNAV 13.46
1999-07-28 - X-dag bonusutdelning ORNBV 13.46
1999-04-09 - X-dag ordinarie utdelning ORNAV 6.50 EUR
1999-04-09 - X-dag ordinarie utdelning ORNBV 6.50 EUR
1998-04-21 - X-dag ordinarie utdelning ORNAV 7.50 EUR
1998-04-21 - X-dag ordinarie utdelning ORNBV 7.50 EUR
1997-04-22 - X-dag ordinarie utdelning ORNAV 5.00 EUR
1997-04-22 - X-dag ordinarie utdelning ORNBV 5.00 EUR
1996-04-23 - X-dag ordinarie utdelning ORNAV 4.00 EUR
1996-04-23 - X-dag ordinarie utdelning ORNBV 4.00 EUR

Beskrivning

LandFinland
ListaLarge Cap Helsinki
SektorHälsovård
IndustriLäkemedel & Handel
Orion är en koncern med verksamhet inom läkemedelsindustrin. Bolaget bedriver forskning och utveckling av humana- och veterinära läkemedel, där störst fokus innehas inom sjukdomar som drabbar nervsystemet, samt onkologi och luftvägssjukdomar. Idag återfinns bolagets produkter på global nivå, med störst närvaro inom Norden och övriga Europa. Bolagets huvudkontor ligger i Esbo, Finland.
2021-01-18 08:00:00

ORION CORPORATION PRESS RELEASE 18 JANUARY 2021 at 9.00 EET             
         

Orion Animal Health and Vetoquinol expand collaboration – Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania  

Orion Animal Health and Vetoquinol are expanding their collaboration with new distribution agreements.

The U.S. Food and Drug Administration FDA granted approval for Orion’s Clevor®, an eye drop indicated for the induction of vomiting in dogs, in June 2020. Under the terms of the related agreement, Vetoquinol will have the right to sell and market Clevor® (ropinirole) in the USA.

On August 1st  2020, Vetoquinol acquired the rights for the Drontal® and Profender® products in the EU and the UK. Effective January 1st 2021, Orion will have the right to sell and market Vetoquinol’s Drontal® and Profender® products in Finland, Hungary and Romania. Drontal® product range is used for the treatment and control of internal parasites in cats and dogs and Profender® for the treatment and control of internal parasites in cats.

These new distribution agreements expand the current collaboration between the two companies under which Vetoquinol has been distributing Orion Animal Health’s sedative products in several European countries since February 2015.

“I’m very pleased to expand our fruitful collaboration with Vetoquinol and have a trusted partner to distribute the latest approved Orion Animal Health innovation in the USA. Also, it is important for us that we can continue to sell Drontal® and Profender® in our home market Finland and expand the distribution to Hungary and Romania”, says Niclas Lindstedt, Vice President of Orion Animal Health.

“We are delighted to reinforce our partnership with Orion. Our Drontal® and Profender® product ranges will benefit from an efficient distribution network in Finland, Hungary and Romania. Moreover, Vetoquinol is proud to be the veterinary laboratory chosen by Orion to develop this innovative Clevor® (ropinirole) brand in the USA. This is a new milestone in our cooperation that demonstrates Vetoquinol’s strong pharmaceutical capabilities and expertise in this key market”, says Matthieu Frechin, CEO of Vetoquinol.

About Orion
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled pulmonary medication under Easyhaler® device portfolio. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

About Vetoquinol
Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets. As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in more than 100 countries through to 24 subsidiaries established in Europe, the Americas and the Asia/Pacific, and a global Export division. Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. At June 30th 2020, Vetoquinol employs 2,401 people.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).

Contact persons:

ORION

Niclas Lindstedt, Vice President Orion Animal Health, Orion Corporation
Tel. +358 10 426 4116

VETOQUINOL

Fanny Toillon, Investor Relations, Vetoquinol
Tel. +33 (03) 84 62 59 88
relations.investisseurs@vetoquinol.com

Emmanuel Dovergne, Investor and Media Relations, Keima Communication
Tel. +33 (0)1 56 43 44 63
Emmanuel.dovergne@keima.fr

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi